Prognosti implications of pigment epithelial detachment in bevacizumab (Avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization

Retina

Volumn 31, Issue 9, 2011, Pages 1812-1818

  Freeman, William R ^a   Kozak, Igor ^a   Yuson, Ritchie Martin S ^a   Nigam, Nitin ^a   Cheng, Lingyun ^a   Mojana, Francesca ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

agerelated macular degeneration; bevacizumab (Avastin); intravitreal; pigment epithelial detachment

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY TREATMENT DIABETIC RETINOPATHY STUDY; FEMALE; HUMAN; MALE; PIGMENT EPITHELIUM; PROGNOSIS; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SCORING SYSTEM; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; TREATMENT RESPONSE; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; PROGNOSIS; RETINAL DETACHMENT; RETINAL PIGMENT EPITHELIUM; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 80053372167     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31821987a4     Document Type: Review

References (23)

1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572.
2. Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: The Rotterdam Study. Arch Ophthalmol 1998; 116:653-658.
3. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology 2001;108:697-704.
4. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047.
5. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372. e5.
6. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina 2006;26:383-390.
7. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: A phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:633. e1-e4.
8. Ladas ID, Kotsolis AI, Papakostas TD, et al. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization. Retina 2007;27: 891-896.
9. Emerson VM, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007;27:439-444.
10. Chen E, Kaiser RS, Vander J. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina 2007;27:445-450.
11. Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: A one-year prospective study. Am J Ophthalmol 2008;145:249-256.
12. Lim JI, Aaberg TM, Capone A Jr., Sternberg P Jr. Indocyanine green angiography-guided photocoagulation of choroidal neovascularization associated with retinal pigment epithelial detachment. Am J Ophthalmol 1997;123:524-532.
13. Gross-Jendroska M, Flaxel CJ, Schwartz SD, et al. Treatment of pigment epithelial detachments due to age-related macular degeneration with intra-ocular C3F8 injection. Aust N Z J Ophthalmol 1998;26:311-317.
14. Axer-Seigel R, Ehrlich R, Rosenblatt I, et al. Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Arch Ophthalmol 2004;122:453-459.
15. Nicolo M, Ghiglione D, Lai S, Calabria G. Intravitreal triamcinolone in the treatment of serous pigment epithelial detachment and occult choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthalmol 2005; 15:415-419.
16. Barondes MJ, Pagliarini S, Chisholm IH, et al. Controlled trial of laser photocoagulation of pigment epithelial detachments in the elderly: 4 year review. Br J Ophthalmol 1992;76:5-7.
17. Hedaya J, Nigam N, Freeman WR. The effect of treatments given to patients before initiation of anti-vascular endothelial growth factor treatment. Retina 2008;28:911-912.
18. Bolz M, Michels S, Geitzenauer W, et al. Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment. Br J Ophthalmol 2007;91:785-789.
19. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twenty-four week results of an uncontrolled open-label clinical study. Ophthalmology 2006;113:2002-2011. e1-e2.
20. Ablonczy, Crosson CE. VEGF modulation of retinal pigment epithelium resistance. Exp Eye Res 2007;86: 762-771.
21. Blaaugeers HG, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for trophic paracrine relation. Am J Pathol 1999;155:421-428.
22. Pauleikhoff D, Löffert D, Spital G, et al. Pigment epithelial detachment in the elderly: Clinical differentiation, natural course and pathogenic implications. Graefes Arch Clin Exp Ophthalmol 2002;240:533-538.
23. Leung CK, Cheung CY, Weinreb RN, et al. Comparison of macular thickness measurements between time-domain and spectral-domain OCT. Invest Ophthalmol Vis Sci 2008;49: 4893-4897.